|
|
||||||||
J Thorac Cardiovasc Surg 1999;118:1097-1100
© 1999 Mosby, Inc.
GENERAL THORACIC SURGERY |
From the University of New Mexico Health Sciences Center, Department of Surgery,a Department of Pathology,b Department of Mathematics and Statistics,c and Department of Medicine,d Albuquerque, NM.
Address for reprints: R. Thomas Temes, MD, University of New Mexico, Department of Surgery, 2211 Lomas Blvd NE, Albuquerque, NM 87131 (E-mail: Ttemes{at}salud.unm.edu ).
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
| Material and methods |
|---|
|
|
|---|
Elective operations were defined as scheduled admissions to the hospital exclusively for the operative procedures. Urgent operations were defined as biopsies performed during hospitalization for respiratory failure in patients not requiring 100% non-rebreather face mask oxygen supplementation or mechanical ventilation. Emergency biopsies were defined as biopsies performed during hospitalization for respiratory failure in patients receiving 100% non-rebreather face mask oxygen supplementation or mechanical ventilation.
Significant beneficial therapeutic changes were defined as new treatments initiated as a result of the lung biopsy. Withdrawal of medications, withdrawal of other therapies, or withdrawal of life support were not considered significant beneficial therapeutic changes. Operative death was defined as death during the same hospitalization or within 30 days of the operation.
Results were analyzed by age, sex, urgency, technique, biopsy site, diagnostic yield, pathologic results, culture results, whether a significant beneficial therapeutic change was made, type of therapy change, and operative mortality rate.
Comparisons between groups were performed with the Fisher exact test for univariable analysis. Multivariable stepwise logistic regression was performed for operative death of all candidate variables. These variables included age, sex, urgency, surgical technique, significant beneficial therapeutic change, and type of therapy change. Histologic diagnosis was established by review of pathologic reports.
| Results |
|---|
|
|
|---|
Open procedures were performed in 0 of 25 of elective operations (0%), in 4 of 17 urgent operations (24%), and in 24 of 27 emergency operations (89%; P < .001). Video thoracoscopic procedures were performed whenever possible. Open procedures were chosen for critically ill patients to minimize operative time, avoid reintubation with a double lumen tube, and abstain from single lung ventilation.
The site of the biopsy was the lingula in 42 cases, left upper lobe otherwise not specified in 1 case, left lower lobe in 27 cases, right upper lobe in 9 cases, right middle lobe in 9 cases, right lower lobe in 16 cases, and unspecified sites in 6 patients. There was no significant difference in the location of the biopsies between the urgency groups (P = .24). Thirty-four patients underwent biopsy of a single location; 31 patients had biopsies obtained from 2 lobes; and 4 patients had biopsies obtained from 3 lobes.
A diagnosis was achieved in 100% of patients. Usual interstitial pneumonia, bronchiolitis, diffuse alveolar damage, honeycomb lung, and pneumonia were the most common diagnoses (Table I). Diffuse alveolar damage was significantly more common in patients requiring emergency treatment; bronchiolitis was significantly more common in the group treated electively, and granulomatous disease (infectious and noninfectious) was significantly more common in those receiving urgent treatment. Otherwise, there were no significant differences in histologic diagnosis between urgency groups.
|
Significant beneficial therapeutic changes were made in 15 of 25 elective biopsies (60%), in 16 of 17 urgent biopsies (94%), in 11 of 27 emergency biopsies (41%), and in 42 of 69 biopsies (61%) overall (P = .001; the changes made for 6 patients are unknown). Significant beneficial therapeutic changes in patients undergoing elective biopsy consisted of treatment with steroids, azathioprine, and/or cyclophosphamide in 13 of 15 patients (87%) and chemotherapy in 2 of 15 patients (13%). Significant beneficial therapeutic changes in patients undergoing urgent biopsy consisted of treatment with steroids, azathioprine, or cyclophosphamide (or a combination) in 9 of 16 patients (82%), antiviral therapy in 1 of 16 patients (6%), antifungal therapy in 2 of 16 patients (13%), antibacterial antibiotics with steroids in 1 of 16 patients (6%), chemotherapy in 1 of 16 patients (6%), and heparin with or without steroids in 2 of 16 patients (13%). Significant beneficial therapeutic changes in patients undergoing emergency biopsy consisted of treatment with steroids, azathioprine, or cyclophosphamide (or a combination) in 9 of 11 patients (82%), antiviral therapy in 1 of 11 patients (9%), and heparin with steroids in 1 of 11 patients (9%). There were no significant differences in the usage of immunosuppression among patients having therapy changes within the 3 urgency groups (P = .14).
No patient died of surgical complications; however, many of the deaths occurred when life support was withdrawn after the diagnosis of irreversible end-stage pulmonary disease was established. Overall operative death occurred in 20 of 73 patients (27%; 2 patients unknown). There were no operative deaths in the elective group, 3 (18%) operative deaths among 17 patients receiving urgent treatment, and 14 (54%) operative deaths among 26 patients requiring emergency treatment. With the use of univariable analysis, operative death was strongly associated with urgency (P < .001) and the use of open surgical technique (P < .001; Table II). With multivariable logistic regression analysis, only urgency remained as significant predictor of operative death (P = .002).
|
| Discussion |
|---|
|
|
|---|
The number of biopsies, size of biopsies, blood loss, operative time, and diagnostic yield are equivalent for open and thoracoscopic techniques. However, duration of chest tube drainage, total days of hospitalization, and total cost are decreased by use of the thoracoscopic technique.
1,2 Therefore our preference is to use thoracoscopic procedures for elective and urgent surgical lung biopsies. We use open biopsies in patients referred for emergency biopsies. These patients are vulnerable to the risks of increased operative time, reintubation with a double-lumen endotracheal tube, and single lung ventilation. Consequently, the urgency and technique of the procedures are closely related. This approach has been advocated by others.
3,4
Laterality and site of biopsy were chosen to facilitate the surgical procedure. All patients in this series had diffuse disease; and, with few exceptions, identification of target regions was unnecessary. The lingula and right middle lobe were frequently sampled. These regions have been shown to be satisfactory locations for lung biopsy.
5,6
Our diagnostic yield was 100%. This compares favorably to reported rates in patients who are immunocompetent of 71% to 100%.
1,7,8 Usual interstitial pneumonia, bronchiolitis, diffuse alveolar damage, honeycomb lung, and pneumonia were our most common diagnoses. Others have reported usual interstitial pneumonia in 27% of patients who are immunocompetent, bronchiolitis in 18% to 26% of patients who are immunocompetent, malignancy in 5% to 13% of patients who are immunocompetent, and infection in 0% to 4% of patients who are immunocompetent.
1,7,8
Previous reports site 0% to 10% yields for bacterial, fungal, and viral cultures in the elective setting.
1,7 In patients who are immunocompetent, infection has been found in only 4% of patients undergoing open lung biopsies.
8 Although we routinely obtained cultures, we found no clinically significant positive cultures for aerobic bacteria, anaerobic bacteria, or mycobacteria. A single fungal culture was clinically useful and resulted in treatment. The few viral, protozoal, and fungal infections in our series were generally diagnosed pathologically. Thus it appeared that routine cultures were not necessary in our series of predominantly patients who were immunocompetent.
Significant beneficial therapeutic changes were made in 61% of our patients as a result of lung biopsy. Previous authors have reported changes in therapy in 46% to 54% of all patients undergoing open lung biopsy and in 18% to 41% of patients who are immunocompetent.
7,8 These data are difficult to interpret because definitions vary between authors. Significant beneficial therapeutic changes in our patients consisted of immunosuppression in 87% of elective cases, 56% of urgent cases, and 82% of emergency cases. Significant beneficial therapeutic changes other than immunosuppression occurred in 11 of 69 of the entire group (16%) in whom therapy after biopsy is known.
Previous reports have documented overall operative mortality rates of 0% to 60%.
7-9 Our overall operative mortality rate was 27%. Operative mortality rates in patients who are immunocompetent has been reported as 0% to 7% with elective treatment, 10% with urgent treatment, and 33% to 66% with emergency treatment; again definitions vary.
4,9-11 Our mortality rate depended significantly on urgency (elective treatment, no deaths; urgent treatment, 18% mortality; emergency treatment, 54% mortality). In many instances, death resulted from the withdrawal of care in patients who were expected to have minuscule chances for recovery. With the use of univariable analysis, urgency and use of open surgical technique were significantly associated with operative death. With multivariable logistic regression analysis, only urgency remained as significant predictor. We and others have been unable to demonstrate decreased operative death between patients who received new therapies after biopsy and those who did not.
4,7,10,12
Should lung biopsy be performed? Patients undergoing elective biopsy have no operative deaths, and 60% obtain significant beneficial therapeutic changes. Patients undergoing urgent biopsy have an 18% operative mortality rate, but 94% receive significant beneficial therapeutic changes. There is no significant difference in operative survival between those with significant beneficial therapeutic changes and those without significant beneficial therapeutic changes. To determine whether lung biopsy is advantageous, a comparison between those who undergo biopsy and those who are treated empirically should be performed. Until then, biopsies are appropriate in elective and urgent situations.
Conversely, patients undergoing emergency biopsy have an operative mortality rate of 54%, and only 7% receive significant beneficial therapeutic changes other than immunosuppression. There is no significant difference in operative survival between those patients receiving significant beneficial therapeutic changes and those patients who do not. A comparison between those patients who undergo biopsy and those patients who are treated empirically should be performed. Until then, these patients should not receive diagnostic surgical procedures if they are in stable condition. They should be treated empirically with immunosuppression without operation if their condition is deteriorating. This approach avoids the risk, cost, and potential liabilities of a surgical procedure that has no apparent or proven benefit to the patient.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. E. Kreider, J. Hansen-Flaschen, N. N. Ahmad, M. D. Rossman, L. R. Kaiser, J. C. Kucharczuk, and J. B. Shrager Complications of Video-Assisted Thoracoscopic Lung Biopsy in Patients with Interstitial Lung Disease Ann. Thorac. Surg., March 1, 2007; 83(3): 1140 - 1144. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Lee, C.-T. Wu, H.-H. Hsu, P.-M. Huang, and Y.-L. Chang Surgical lung biopsy for diffuse pulmonary disease: Experience of 196 patients J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 984 - 990. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yamaguchi, I. Yoshino, R. Suemitsu, A. Osoegawa, T. Kameyama, T. Tagawa, S. Fukuyama, and Y. Maehara Elective Video-Assisted Thoracoscopic Lung Biopsy for Interstitial Lung Disease Asian Cardiovasc Thorac Ann, March 1, 2004; 12(1): 65 - 68. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |